National Cancer Institute chooses Luna's agent for preclinical characterization

The National Cancer Institute has selected Luna Innovations’ MRI contrast agent as a candidate for preclinical characterization by the Nanotechnology Characterization Laboratory.

Luna said the contrast agent is a modified fullerene compound with the potential to provide a completely new approach to enhancing contrast during MRI procedures.

The technology may also prevent the toxicity currently associated with gadolinium, an MRI contrast substance which has been associated with health problems, according to the Roanoke, Va.-based company.

Luna Innovations engages in the research, development and commercialization of technologies in the areas of molecular technology solutions and sensing solutions.